X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5606) 5606
Publication (607) 607
Newsletter (270) 270
Book Review (129) 129
Magazine Article (22) 22
Book Chapter (18) 18
Book / eBook (11) 11
Data Set (6) 6
Dissertation (6) 6
Conference Proceeding (4) 4
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4037) 4037
pharmacology & pharmacy (3389) 3389
index medicus (2812) 2812
animals (2141) 2141
cytochrome p-450 (2031) 2031
cytochrome p-450 enzyme system - metabolism (2007) 2007
male (2004) 2004
metabolism (1578) 1578
toxicology (1321) 1321
cytochrome p450 (1238) 1238
female (1225) 1225
drug interactions (1216) 1216
pharmacokinetics (1130) 1130
rats (1103) 1103
microsomes, liver - enzymology (951) 951
in-vitro (922) 922
enzymes (890) 890
cytochrome p-450 enzyme inhibitors (874) 874
physiological aspects (858) 858
adult (836) 836
microsomes, liver - metabolism (785) 785
enzyme inhibitors - pharmacology (775) 775
liver (764) 764
microsomes, liver - drug effects (744) 744
inhibition (699) 699
cytochrome p-450 enzyme system - genetics (670) 670
analysis (669) 669
cytochrome p-450 cyp1a2 - metabolism (639) 639
human liver-microsomes (623) 623
biochemistry & molecular biology (618) 618
metabolites (610) 610
middle aged (593) 593
induction (569) 569
research (564) 564
expression (558) 558
mice (557) 557
dose-response relationship, drug (552) 552
kinetics (541) 541
liver - enzymology (523) 523
pharmacology/toxicology (504) 504
liver - drug effects (488) 488
rats, sprague-dawley (464) 464
biotransformation (460) 460
cytochrome p-450 cyp3a (453) 453
cytochrome p-450 cyp3a - metabolism (446) 446
hydroxylation (418) 418
isoenzymes - metabolism (412) 412
pharmacology (412) 412
aryl hydrocarbon hydroxylases - metabolism (394) 394
in vitro techniques (390) 390
liver - metabolism (390) 390
pharmacogenetics (389) 389
cytochrome p-450 cyp1a1 - metabolism (385) 385
drugs (384) 384
cancer (367) 367
area under curve (366) 366
chemistry, medicinal (366) 366
drug metabolism (366) 366
genotype (357) 357
aged (348) 348
cyp1a2 (343) 343
rat (339) 339
cytochrome (337) 337
cyp3a4 (336) 336
cells, cultured (331) 331
chromatography, high pressure liquid (331) 331
microsomes (325) 325
cytochrome p-450 cyp1a2 inhibitors (322) 322
cytochrome p-450 enzyme system - biosynthesis (298) 298
biomedicine (294) 294
substrate specificity (292) 292
drug-metabolism (290) 290
enzyme induction - drug effects (290) 290
cyp2d6 (280) 280
toxicity (279) 279
hepatocytes - drug effects (277) 277
aryl hydrocarbon hydroxylases - genetics (276) 276
cytochrome p-450 cyp2d6 - metabolism (275) 275
gene expression (270) 270
article (269) 269
p-glycoprotein (269) 269
drug-drug interactions (268) 268
drug-interactions (268) 268
identification (266) 266
mass spectrometry (263) 263
oxidation (262) 262
administration, oral (259) 259
rats, wistar (259) 259
genetic aspects (258) 258
recombinant proteins - metabolism (258) 258
young adult (257) 257
activation (254) 254
gene-expression (250) 250
pharmaceutical preparations - metabolism (250) 250
enzyme induction (249) 249
medicine & public health (248) 248
cytochrome p-450 cyp2c19 (246) 246
cytochromes p450 (246) 246
aryl hydrocarbon hydroxylases (242) 242
polymorphism, genetic (240) 240
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5905) 5905
Chinese (13) 13
Japanese (6) 6
Spanish (3) 3
Russian (2) 2
French (1) 1
German (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2017, Volume 60, Issue 15, pp. 6678 - 6692
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers.... 
TARGET | CHEMISTRY, MEDICINAL | PATHWAY | MECHANISMS | BETA-CATENIN | WNT | CANCER | Acyltransferases - antagonists & inhibitors | Maleimides - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Microsomes, Liver - metabolism | Maleimides - pharmacology | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Maleimides - pharmacokinetics | Cytochrome P-450 CYP1A2 Inhibitors - pharmacokinetics | Maleimides - chemical synthesis | HEK293 Cells | Pyridazines - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - pharmacology | Wnt Signaling Pathway | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Rats | Cytochrome P-450 CYP1A2 Inhibitors - chemical synthesis | Cytochrome P-450 CYP2D6 Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - chemical synthesis | Xenograft Model Antitumor Assays | Animals | Cytochrome P-450 CYP1A2 Inhibitors - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - chemical synthesis | High-Throughput Screening Assays | Membrane Proteins - antagonists & inhibitors | Mice, Nude | Cytochrome P-450 CYP1A2 Inhibitors - administration & dosage | Cell Line, Tumor | Pyridazines - pharmacokinetics | Mice, Inbred BALB C
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2018, Volume 81, Issue 1, pp. 73 - 80
Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1–3, FGFR 1–3, and PDGFR. This study was performed to investigate the... 
Fluvoxamine CYP1A2 | Medicine & Public Health | Dovitinib | Drug–drug interaction | Oncology | Cancer Research | TKI258 | Pharmacology/Toxicology | PHASE-II | OPEN-LABEL | SORAFENIB | CANCER | FLUOXETINE | FGFR | RENAL-CELL CARCINOMA | TRIAL | METABOLISM | ONCOLOGY | VEGFR | PHARMACOLOGY & PHARMACY | Drug-drug interaction | Area Under Curve | Humans | Middle Aged | Half-Life | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Drug Interactions | Fluvoxamine - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Quinolones - pharmacokinetics | Quinolones - therapeutic use | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP1A2 Inhibitors - adverse effects | Benzimidazoles - therapeutic use | Cytochrome P-450 CYP1A2 Inhibitors - therapeutic use | Fluvoxamine - therapeutic use | Drug Administration Schedule | Benzimidazoles - pharmacokinetics | Fluvoxamine - pharmacology | Neoplasms - drug therapy | Maximum Tolerated Dose | Quinolones - administration & dosage | Cytochrome P-450 CYP1A2 Inhibitors - pharmacology | Cytochrome P-450 CYP1A2 Inhibitors - administration & dosage | Aged | Tyrosine | Complications and side effects | Care and treatment | Drug interactions | Cytochrome P-450 | Pharmaceutical industry | Vascular endothelial growth factor | Tumors | Toxicity | Cytochrome P450 | Breast cancer | Pharmacology | CYP1A2 protein | Patients | Coefficient of variation | Steady state | Vascular endothelial growth factor receptors | Confidence intervals | Inhibitors | Drug interaction | Solid tumors | Pharmacokinetics | Drug dosages | Protein-tyrosine kinase | Fluvoxamine | Cancer | Smoking | Fibroblast growth factor receptors | Index Medicus
Journal Article
Journal Article